AptarGroup, Inc
AptarGroup designs and manufactures dosing, dispensing, sealing and protection technologies used in drug delivery and consumer packaging. The company sells into pharmaceutical, fragrance, skincare, cosmetics, food, beverage, personal care and home care markets, where customers need precise product delivery, contamination protection and differentiated packaging functionality. It operates through three reporting segments: Pharma, Beauty and Closures. Aptar is headquartered in Crystal Lake, Illinois and runs manufacturing and sales operations across North America, Europe, Asia and Latin America.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProprietary dispensing systems, drug delivery systems, injectables components, active material science solutions and related services for prescription drug and consumer health markets.
Dispensing systems and sealing solutions for fragrance, facial skincare, color cosmetics and related beauty applications.
Dispensing closures, sealing solutions and food service trays used across food, beverage, personal care, home care and beauty markets.
Customers
Aptar sells primarily to branded consumer goods companies, pharmaceutical manufacturers and healthcare customers that need reliable, high-precision packaging components. In Pharma, customers include prescription drug, consumer health care and injectables companies that value regulatory support, safety of supply and specialized delivery formats. In Beauty, the customer base includes fragrance, skincare and cosmetics brands that use Aptar's dispensing systems to improve user experience and product differentiation. In Closures, Aptar serves food, beverage, personal care and home care customers that need functional closures, sealing performance and packaging convenience. The company has about 5,000 customers, and no single customer or affiliated group accounted for more than 4% of 2025 net sales, which reduces concentration risk.
Buys drug delivery systems, injectables components, sealing solutions and pharma packaging to improve dosing accuracy, compliance and product protection.
Buys dispensing systems for fragrance, facial skincare and color cosmetics to support premium positioning and differentiated user experience.
Buys closures, sealing solutions and food service trays to protect products, improve convenience and support packaging performance.
Buys pumps, closures and sealing solutions for soaps, cleaners and related products where functionality and cost efficiency matter.
Buys specialized components for ophthalmic, injectables and active material science applications where regulatory and technical requirements are high.
Strategy
Aptar's strategy centers on innovation in proprietary dispensing, dosing and protection technologies that can be sold across multiple end markets. The company emphasizes engineering, materials science, regulatory expertise and manufacturing scale as differentiators against regional and global competitors. It is also investing in capacity, equipment and new product development to support growth, while preserving the ability to generate cash for dividends, acquisitions and share repurchases. Management highlights sustainability-related product redesign, lower-carbon logistics and local manufacturing as part of its competitive positioning with customers and regulators.
Proprietary technology is the main source of pricing power and customer retention in a highly competitive packaging market.
Customers increasingly prefer suppliers that can provide short lead times, service and supply security in multiple regions.
Regulatory and customer pressure on recycled content, recyclability and carbon footprint can reshape demand and product specifications.
Cash generation is used to fund growth investments while supporting dividends, acquisitions and buybacks.
Geography
Q1/2026Aptar operates globally, with manufacturing facilities across North America, Europe, Asia and Latin America and employees in approximately 20 countries. The company is headquartered in the United States, but its customer base and production footprint are international, which helps it serve multinational brands with local supply and shorter lead times. Management notes that customers increasingly prefer local suppliers for reactivity, service and safety of supply, especially in beauty and personal care. The company also faces exposure to regional cost structures, trade restrictions and currency translation, while its broad footprint supports resilience and customer proximity.
Share of the revenue the company reports by geography.
Risks
Aptar operates in highly competitive markets where price pressure is persistent and local or regional competitors can undercut global suppliers. The company is exposed to regulatory change because its products and many customer end products must comply with FDA and other agency requirements, and changes in packaging rules can force redesigns or delay revenue. It also faces litigation and IP risk, including patent infringement and antitrust claims referenced in recent filings, which can create legal expense, injunction risk and operational disruption. Raw material availability and cost, especially PCR resins, can affect production economics, while tariffs, trade restrictions and macroeconomic weakness can reduce customer demand and pressure cash flow. Because Aptar has significant international operations, it also carries foreign exchange, tax and geopolitical exposure across Europe, Asia and Latin America.
- Regulatory and product compliance changesImpact: HighLikelihood: Medium
FDA and comparable agencies can delay approvals or require design changes, which can postpone revenue and increase development costs.
Exposure: Pharma and regulated consumer products
- Litigation and intellectual property disputesImpact: HighLikelihood: Low
Recent patent infringement and antitrust actions could lead to damages, injunctions or business interruption.
Exposure: Ophthalmic and other specialized products
- Price competition from regional and global packaging suppliersImpact: High
Aptar sells standardized and engineered components in markets where customers can switch suppliers based on price, service and lead time.
Exposure - Raw material cost and availabilityImpact: MediumLikelihood: High
PCR resins and other inputs can become more expensive or scarce, affecting output and customer pricing.
Exposure: Closures and Beauty
- Trade, tariff and macro demand weaknessImpact: MediumLikelihood: High
Tariffs, inflation and slower consumer or pharma demand can reduce volumes and constrain capital spending.
Exposure: Global operations
Accounting
Judgemental itemsThe company has about $1.08 billion of goodwill allocated across reporting units, and impairment depends on future cash flow and discount rate assumptions.
Impact: A write-down would reduce operating income and equity.
Management removed indefinite reinvestment assertions for certain foreign earnings, creating deferred tax liabilities and possible repatriation tax expense.
Impact: Can affect tax expense, balance sheet liabilities and cash tax planning.
Patent infringement and antitrust claims may require accruals or disclosures depending on outcome and probability assessments.
Impact: Can affect operating expenses and contingent liability disclosures.
Adjusted EBITDA and adjusted earnings exclude restructuring, acquisition costs and other special items, which can obscure underlying trend analysis.
Impact: Impacts comparability and valuation multiples.
Similar listed companies
Publicly listed companies with a comparable business focus.
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Amphastar Pharmaceuticals, Inc.
AMPH · Pharmaceutical Preparations
SPAR Group, Inc.
SGRP · Services-Business Services, NEC
Avantor, Inc.
AVTR · Laboratory Analytical Instruments
Septerna, Inc.
SEPN · Pharmaceutical Preparations
Septerna is a U.S.-based biotechnology company focused on discovering and developing small-molecule medicines for diseases driven by G protein-coupled receptors (GPCRs).
Amcor plc
AMCR · Miscellaneous Manufacturing Industries
Amcor plc is a packaging company that designs and manufactures flexible packaging, rigid packaging, cartons, and closures for consumer and healthcare-related end markets.
Last updated: 24/09/2026